MedTrace Logo

Role of L-citrulline in Prevention of Pregnancy Associated Hypertension

NCT04979793 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 338

Last updated 2025-09-19

No results posted yet for this study

Summary

The target population for our study is healthy nulliparous pregnant women (first pregnancy) between the 12-16 week of pregnancy.

If a subject is eligible, written consent will be obtained by person to person contact. Eligible participants will be randomized to receive either daily L-citrulline supplementation or placebo.

Conditions

  • Pregnancy Induced Hypertension
  • Preeclampsia and Eclampsia
  • Gestational Hypertension

Interventions

DRUG

L-citrulline

3 gram sachet, L-citrulline

DRUG

Placebo

Milk powder placebo

Sponsors & Collaborators

  • The University of Texas Medical Branch, Galveston

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-28
Primary Completion
2027-07-30
Completion
2027-07-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04979793 on ClinicalTrials.gov